title: Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
abstract: Coadministration of nevirapine-based antiretroviral therapy (ART) and artemether-lumefantrine is reported to result in variable changes in lumefantrine exposure. We conducted an intensive pharmacokinetic study with 11 HIV-infected adults who were receiving artemether-lumefantrine plus nevirapine-based ART, and we compared the results with those for 16 HIV-negative adult historical controls. Exposure to artemether and lumefantrine was significantly lower and dihydroartemisinin exposure was unchanged in subjects receiving nevirapine-based ART, compared with controls. Nevirapine exposure was unchanged before and after artemether-lumefantrine administration.
authors.affiliation: Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA sunil.parikh@yale.edu.
authors.forename: Sunil
authors.initials: S
authors.lastname: Parikh
authors.affiliation: Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria Department of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria.
authors.forename: Fatai
authors.initials: F
authors.lastname: Fehintola
authors.affiliation: Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
authors.forename: Liusheng
authors.initials: L
authors.lastname: Huang
authors.affiliation: Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
authors.forename: Alexander
authors.initials: A
authors.lastname: Olson
authors.affiliation: Department of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria.
authors.forename: Waheed A
authors.initials: WA
authors.lastname: Adedeji
authors.affiliation: Division of Infectious Diseases and Center for Global Health, Northwestern University, Chicago, Illinois, USA.
authors.forename: Kristin M
authors.initials: KM
authors.lastname: Darin
authors.affiliation: Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, Department of Pharmacy Practice, University at Buffalo, Buffalo, New York, USA.
authors.forename: Gene D
authors.initials: GD
authors.lastname: Morse
authors.affiliation: Division of Infectious Diseases and Center for Global Health, Northwestern University, Chicago, Illinois, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Murphy
authors.affiliation: Division of Infectious Diseases and Center for Global Health, Northwestern University, Chicago, Illinois, USA.
authors.forename: Babafemi O
authors.initials: BO
authors.lastname: Taiwo
authors.affiliation: Department of Pediatrics, University of Ibadan, Ibadan, Nigeria.
authors.forename: Olusegun O
authors.initials: OO
authors.lastname: Akinyinka
authors.affiliation: Department of Obstetrics and Gynecology, University of Ibadan, Ibadan, Nigeria.
authors.forename: Isaac F
authors.initials: IF
authors.lastname: Adewole
authors.affiliation: Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
authors.forename: Francesca T
authors.initials: FT
authors.lastname: Aweeka
authors.affiliation: Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, Nebraska, USA.
authors.forename: Kimberly K
authors.initials: KK
authors.lastname: Scarsi
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000962:Antimalarials / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D000077549:Artemether; D037621:Artemisinins / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D016022:Case-Control Studies; D060085:Coinfection; D004338:Drug Combinations; D004347:Drug Interactions; D004983:Ethanolamines / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D005260:Female; D005449:Fluorenes / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006801:Humans; D000078102:Lumefantrine; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000469:parasitology; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use*; D009549:Nigeria; D010963:Plasmodium falciparum / Q000187:drug effects / Q000502:physiology
chemical_list: D019380:Anti-HIV Agents; D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; C039060:artenimol; D019829:Nevirapine; D000077549:Artemether; D000078102:Lumefantrine